Table 1. Baseline and clinical characteristics of the 30 advanced stage non-small cell lung cancer patients and 20 matched healthy controls.
| Healthy subjectsN = 20 | Cancer patientsN = 30 | P value | |
| Age, years | 61.4±12.6 | 62±11.9 | 0.855 |
| Male, n (%) | 12 (60) | 21 (70) | 0.465 |
| Co-morbidity, n (%) | |||
| Hypertension | 9 (45) | 11 (36.7) | 0.556 |
| Diabetes mellitus | 4 (20) | 3 (10) | 0.318 |
| Chronic obstructive pulmonary disease | 5 (25) | 10 (33.3) | 0.529 |
| Heart failure | 2 (10) | 1 (3.3) | 0.331 |
| Chronic hepatitis | 1 (5) | 3 (10) | 0.523 |
| Chronic renal failure | 3 (15) | 2 (6.7) | 0.336 |
| Smoking history, n (%) | 0.447 | ||
| Never | 8 (66.7) | 15 (50) | |
| Remote | 2 (16.7) | 11 (36.7) | |
| Current | 2 (16.7) | 4 (13.3) | |
| Tumor Stage, n (%) | |||
| IIIB | 14 (46.67) | ||
| IV | 16 (53.33) | ||
| Histopathology, n (%) | |||
| Squamous cell carcinoma | 9 (30) | ||
| Adenocarcinoma | 21 (70) | ||
| ECOG performance status, n (%) | |||
| 0 | 3 (10) | ||
| 1 | 22 (73.3) | ||
| 2 | 5 (16.7) | ||
| Response to first line chemotherapy, n (%) | |||
| Partial response | 9 (30) | ||
| Stable disease | 13 (43.3) | ||
| Progressive disease | 8 (26.7) |
ECOG = Eastern Cooperative Oncology Group.